Geron Corp (GERN)

$1.76 +0.05 (2.92%)
Market Cap 1.11B
Revenue (ttm) 183.88M
Net Income (ttm) -83.50M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -45.41%
Debt to Equity Ratio 0.53
Volume 17,943,701
Avg Vol 19,007,273
Day's Range N/A - N/A
Shares Out 640.55M
Stochastic %K 72%
Beta 0.67
Analysts Sell
Price Target $3.40

Company Profile

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractor...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 473 7700
Address:
919 East Hillsdale Boulevard, Suite 250, Foster City, United States
ZoeyTanner
ZoeyTanner Apr. 10 at 2:31 PM
$GERN For three decades, the ceo's and Semerjian have been on the Geron Corp gravy train. With retail throw off the track at every stop. Most impressive is the 1.70 pps after eternity. Great work guys, if only I could have had a job like this. Over promise, zero results.
0 · Reply
meistermell
meistermell Apr. 9 at 11:05 PM
$GERN there's at least a 20% possibility this gets bought out on 2026. Ticks a lot of boxes
2 · Reply
GangsterX
GangsterX Apr. 9 at 8:05 PM
$PMVP $GERN $ALLO still holding all 3 but i sold ALLO half. pMVP will run up soon
0 · Reply
Huntlardo
Huntlardo Apr. 9 at 7:05 PM
$GERN was looking good this morning volume fell off a cliff around lunch.
0 · Reply
ZaraSeagrove
ZaraSeagrove Apr. 9 at 5:06 PM
$GERN What is short volume, short interest, and the short float -- not sure I understand the difference between the three -- doing now? Shorting a stock whose biotech is showing the world a cure for blood cancers is outrageous, period. Current evidence shows Rytelo will be used globally and for the good. What would these shorts feel if and when they or their loved ones get even one of the many existent blood cancers?
1 · Reply
stanky_dank27
stanky_dank27 Apr. 9 at 3:56 PM
$GERN setting up nicely for an afternoon run.
0 · Reply
GISBlaster98
GISBlaster98 Apr. 9 at 11:25 AM
$GERN Saw this from a Geron post on LinkedIn! Good news ….https://www.nature.com/articles/s41408-026-01501-2
0 · Reply
tackinis
tackinis Apr. 9 at 12:33 AM
$IOVA $GERN bullish. Also $ASST will touch $16 if bitcoin touch $87K .
1 · Reply
ZoeyTanner
ZoeyTanner Apr. 8 at 3:00 PM
$GERN Geron figures, only red on the screen
1 · Reply
Huntlardo
Huntlardo Apr. 8 at 2:19 PM
$GERN low volume pull back, looking for 1.66 area to hold as support.
0 · Reply
Latest News on GERN
Geron to Participate in the 25th Annual Needham Virtual Healthcare Conference

Apr 6, 2026, 8:00 AM EDT - 4 days ago

Geron to Participate in the 25th Annual Needham Virtual Healthcare Conference

Geron Announces Appointment of New Members to its Board of Directors

Mar 26, 2026, 8:00 AM EDT - 15 days ago

Geron Announces Appointment of New Members to its Board of Directors

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 18, 2026, 4:05 PM EDT - 22 days ago

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Geron Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Feb 25, 2026, 7:00 AM EST - 6 weeks ago

Geron Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Geron Plans to Present at Upcoming Investor Conferences

Feb 23, 2026, 8:00 AM EST - 6 weeks ago

Geron Plans to Present at Upcoming Investor Conferences

Top 3 Health Care Stocks That May Collapse This Quarter

Feb 18, 2026, 9:04 AM EST - 7 weeks ago

Top 3 Health Care Stocks That May Collapse This Quarter

AZN MASI

Geron Plans to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026

Feb 11, 2026, 7:27 AM EST - 2 months ago

Geron Plans to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026

Geron Corporation Provides 2026 Financial Guidance

Jan 12, 2026, 8:00 AM EST - 3 months ago

Geron Corporation Provides 2026 Financial Guidance

Geron Corporation Announces Strategic Restructuring Plan to Position the Company for Long-Term Value Creation

Dec 11, 2025, 8:00 AM EST - 4 months ago

Geron Corporation Announces Strategic Restructuring Plan to Position the Company for Long-Term Value Creation

Geron Corporation Presents New Data at ASH 2025 Highlighting the Relationship Between Treatment-Emergent Cytopenias and Clinical Benefit of RYTELO® (Imetelstat) in Lower-Risk MDS

Dec 8, 2025, 8:02 AM EST - 4 months ago

Geron Corporation Presents New Data at ASH 2025 Highlighting the Relationship Between Treatment-Emergent Cytopenias and Clinical Benefit of RYTELO® (Imetelstat) in Lower-Risk MDS

Geron Corporation Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Nov 5, 2025, 7:00 AM EST - 5 months ago

Geron Corporation Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Geron Corporation to Present at Upcoming Investor Conferences

Nov 4, 2025, 8:00 AM EST - 5 months ago

Geron Corporation to Present at Upcoming Investor Conferences

Geron Corporation Announces Five Presentations Selected for ASH 2025 Highlighting Clinical Activity of RYTELO® (imetelstat) in Myeloid Hematologic Malignancies

Nov 3, 2025, 9:05 AM EST - 5 months ago

Geron Corporation Announces Five Presentations Selected for ASH 2025 Highlighting Clinical Activity of RYTELO® (imetelstat) in Myeloid Hematologic Malignancies

Geron Plans to Announce Third Quarter 2025 Financial Results on November 5, 2025

Oct 27, 2025, 8:00 AM EDT - 5 months ago

Geron Plans to Announce Third Quarter 2025 Financial Results on November 5, 2025

Geron Corporation Announces Executive Leadership Transitions and Appointments

Oct 13, 2025, 4:34 PM EDT - 6 months ago

Geron Corporation Announces Executive Leadership Transitions and Appointments

Geron to Participate in the 2025 Wells Fargo Healthcare Conference

Aug 27, 2025, 4:05 PM EDT - 8 months ago

Geron to Participate in the 2025 Wells Fargo Healthcare Conference

Geron Corporation Investors: Company Investigated by the Portnoy Law Firm

Aug 14, 2025, 5:23 PM EDT - 8 months ago

Geron Corporation Investors: Company Investigated by the Portnoy Law Firm

Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Aug 8, 2025, 4:01 PM EDT - 8 months ago

Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Geron Corporation Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Aug 6, 2025, 7:01 AM EDT - 8 months ago

Geron Corporation Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Geron Appoints Harout Semerjian as President and Chief Executive Officer

Aug 6, 2025, 7:00 AM EDT - 8 months ago

Geron Appoints Harout Semerjian as President and Chief Executive Officer

Geron Plans to Announce Second Quarter 2025 Financial Results on August 6, 2025

Jul 28, 2025, 8:00 AM EDT - 9 months ago

Geron Plans to Announce Second Quarter 2025 Financial Results on August 6, 2025

Geron Announces Presentations at ASCO and EHA Underscoring RYTELO® (imetelstat) Efficacy and Safety Across Range of LR-MDS Patients, and Showcasing Momentum of Myelofibrosis Program

May 28, 2025, 8:30 AM EDT - 11 months ago

Geron Announces Presentations at ASCO and EHA Underscoring RYTELO® (imetelstat) Efficacy and Safety Across Range of LR-MDS Patients, and Showcasing Momentum of Myelofibrosis Program

GERN Investors Have Opportunity to Join Geron Corporation Fraud Investigation with the Schall Law Firm

May 8, 2025, 11:24 PM EDT - 1 year ago

GERN Investors Have Opportunity to Join Geron Corporation Fraud Investigation with the Schall Law Firm

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 12, 2025 in Geron Lawsuit – GERN

May 7, 2025, 12:33 PM EDT - 1 year ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 12, 2025 in Geron Lawsuit – GERN

Geron Corporation Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 7, 2025, 7:00 AM EDT - 1 year ago

Geron Corporation Reports First Quarter 2025 Financial Results and Recent Business Highlights

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Geron

Apr 24, 2025, 9:33 PM EDT - 1 year ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Geron

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 18, 2025, 4:30 PM EDT - 1 year ago

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Geron

Apr 9, 2025, 10:40 AM EDT - 1 year ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Geron

Geron Plans to Announce First Quarter 2025 Financial Results on May 7, 2025

Mar 31, 2025, 4:30 PM EDT - 1 year ago

Geron Plans to Announce First Quarter 2025 Financial Results on May 7, 2025

ZoeyTanner
ZoeyTanner Apr. 10 at 2:31 PM
$GERN For three decades, the ceo's and Semerjian have been on the Geron Corp gravy train. With retail throw off the track at every stop. Most impressive is the 1.70 pps after eternity. Great work guys, if only I could have had a job like this. Over promise, zero results.
0 · Reply
meistermell
meistermell Apr. 9 at 11:05 PM
$GERN there's at least a 20% possibility this gets bought out on 2026. Ticks a lot of boxes
2 · Reply
GangsterX
GangsterX Apr. 9 at 8:05 PM
$PMVP $GERN $ALLO still holding all 3 but i sold ALLO half. pMVP will run up soon
0 · Reply
Huntlardo
Huntlardo Apr. 9 at 7:05 PM
$GERN was looking good this morning volume fell off a cliff around lunch.
0 · Reply
ZaraSeagrove
ZaraSeagrove Apr. 9 at 5:06 PM
$GERN What is short volume, short interest, and the short float -- not sure I understand the difference between the three -- doing now? Shorting a stock whose biotech is showing the world a cure for blood cancers is outrageous, period. Current evidence shows Rytelo will be used globally and for the good. What would these shorts feel if and when they or their loved ones get even one of the many existent blood cancers?
1 · Reply
stanky_dank27
stanky_dank27 Apr. 9 at 3:56 PM
$GERN setting up nicely for an afternoon run.
0 · Reply
GISBlaster98
GISBlaster98 Apr. 9 at 11:25 AM
$GERN Saw this from a Geron post on LinkedIn! Good news ….https://www.nature.com/articles/s41408-026-01501-2
0 · Reply
tackinis
tackinis Apr. 9 at 12:33 AM
$IOVA $GERN bullish. Also $ASST will touch $16 if bitcoin touch $87K .
1 · Reply
ZoeyTanner
ZoeyTanner Apr. 8 at 3:00 PM
$GERN Geron figures, only red on the screen
1 · Reply
Huntlardo
Huntlardo Apr. 8 at 2:19 PM
$GERN low volume pull back, looking for 1.66 area to hold as support.
0 · Reply
vonryan
vonryan Apr. 8 at 2:13 PM
$GERN A red morning in which buying on the dip.
0 · Reply
dgreenway
dgreenway Apr. 7 at 11:24 PM
$GERN I cannot believe Trump gave those scumbags a 2 week ceasefire.
3 · Reply
blankstocker
blankstocker Apr. 7 at 9:07 PM
$GERN 2025 annual report is out. https://ir.geron.com/static-files/75996468-7453-48ec-8488-44c7b462431c
0 · Reply
Twillery
Twillery Apr. 7 at 5:55 PM
$GERN People are confusing accelerated approval by the FDA with stopped for efficacy by the DSMB. They're two different things. Only about 5% to 10% of drugs each year are stopped for efficacy, and the number drops to around 1.7% for blood cancer drugs, and in Geron's case the DSMB is looking for overall survival(OS), not progression-free survival(PFS), which means the tumor basically stopped growing. It's a very high, very elite bar to overcome, so I wouldn't be too disappointed if the DSMB recommends continuation, which is just a way to gain more certainty; that is, the drug is still a great drug, but the DSMB wants to wait a couple of years.
0 · Reply
Huntlardo
Huntlardo Apr. 7 at 4:35 PM
$GERN Xbi down 1% with a put to call ratio over 6 and we are cooking. market wants gern shares this week!
0 · Reply
Twillery
Twillery Apr. 7 at 3:29 AM
$GERN I'm following the comments that say there's been a huge increase in Geron's trading volume this past week or so. Why and who is the question: Is it because institutions & individual investors are betting on the earnings release next month? Or is it due to the upcoming reading of ImpactMF's interim phase 3 results? Or both? What worries me, though it's doubtful, is institutional investors' selling chunks piecemeal because they have insider knowledge of something negative. I don't want to find out in late 2026 that the top-heavy institutions, or even one institution, sold because of insider knowledge, which is what happened to a small biotech I invested in years ago. Too bad we can't find out in real time if they're selling. That said, all indications tilt towards positive, not negative, news
2 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Apr. 7 at 1:05 AM
Attached is a history of all commercial-stage oncology & non-oncology focused biopharma M&A exits by month & year since 1/1/2017. Our apologies for not tracking both peer groups in the same format It's been hot with DAWN, APLS & SLNO but notice this time the last few years was just as hot. If history is any guide there will be at least 1 or 2 in each peer group by the end of June. $ANAB may be a candidate after announcing the spin-off $GERN has been running but we think there is no universe they sell until after the data read $KALV has been one of the strongest stocks in commercial-stage oncology. It will be 1 year since approval (7/7/25) $MDGL finally? Don't forget fully diluted shares are ~35% higher than traditional $CYTK per a user we respect. This is not investment advice. We're just sharing our calendars for entertainment purposes only.
2 · Reply
GISBlaster98
GISBlaster98 Apr. 6 at 9:29 PM
$GERN I think this is simply the best overview of GERN that I have heard. Easy to understand and does a great job explaining the company…https://www.google.com/url?q=https://www.youtube.com/watch%3Fv%3DWWGQTQsJgWc&sa=U&ved=2ahUKEwj3tODklNqTAxXJrokEHa9qHuMQz40FegQIXBAJ&usg=AOvVaw0PM_UlL44ogPsAZpTPFm4D
0 · Reply
Digitcipher
Digitcipher Apr. 6 at 9:13 PM
$GERN ChatGPT is wrong on both counts about why the stock is moving. The market is looking at the accrual of management's plan of aligning expenses to attain profitability. That's more in focus than anything else. If they show meaningful progress on that, the stock will rocket. The clinical trials are pure bonus and not being discounted into the stock price at this point.
0 · Reply
Huntlardo
Huntlardo Apr. 6 at 8:50 PM
$GERN roughly 10 mill logged after the bell. 33 mill friday and 39 mill today. whos positioning for what?
1 · Reply
BullsOnPrade
BullsOnPrade Apr. 6 at 8:49 PM
$GERN momentum building, stacking wins
0 · Reply
MrWaikoloa
MrWaikoloa Apr. 6 at 8:41 PM
$GERN Chart is looking beautiful. Looks primed to take out the one year high.
0 · Reply